Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY, a HUMIRA biosimilar, available to patients

01.06.2023 - –  YUSIMRY (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company  – –  YUSIMRY will be available on costplusdrugs.com for $569.27 plus dispensing and shipping fees  – DALLAS, Texas and REDWOOD CITY, ... Seite 1

Related Keywords

Dallas ,Texas ,United States ,Cuba ,America ,Cuban ,Alex Oshmyansky ,Denny Lanfear ,Mark Cuban Cost Plus Drug Company ,Nasdaq ,Team Cuban Card ,Coherus Biosciences Inc ,Cuban Cost Plus Drug Company ,Cuban Cost Plus Drug ,Coherus Biosciences ,Mark Cuban Cost Plus Drug ,Cost Plus Drugs ,Chief Executive Officer ,Cost Plus ,